Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Irum Khan"'
Autor:
Irum Khan, Andrei L. Gartel
Publikováno v:
Blood Advances. 6:4028-4030
Autor:
Ivy Elizabeth, Abraham, Anand Ashwin, Patel, Heidy, Wang, John Patrick, Galvin, Olga, Frankfurt, Li, Liu, Irum, Khan
Publikováno v:
Cancer causescontrol : CCC. 32(7)
Racial disparities in acute myeloid leukemia (AML) have been reported but the relative contribution of disease versus patient-specific factors including comorbidities and access to care is unclear.We conducted a retrospective analysis of patient char
Autor:
Irum Khan, Nandini Kalakota, Andrei L. Gartel, Olga Frankfurt, Marianna Halasi, Nadim Mahmud, Anand Patel, Yi Hua Chen, Nathan Aardsma, Li Liu, Rachael Schultz, John D. Crispino
Publikováno v:
JCI Insight
Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. Our previous work has shown that these favorable outcomes are linked to the cytoplasmic relocalization and inactivation of F
Autor:
Victor R. Gordeuk, Damiano Rondelli, John G. Quigley, Yi Fan Chen, Ronald Hoffman, David Peace, Irum Khan, Pritesh R. Patel, Santosh L. Saraf, Ardaman Shergill
Publikováno v:
Clinical lymphoma, myelomaleukemia. 16(6)
Background The Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are characterized by an increased risk of thrombotic and hemorrhagic complications. Large retrospective studies have demonstrated racial disparities in MPN outcomes a
Autor:
Monika J. Stankiewicz, Priya Koppikar, Brady L. Stein, Lauren Diebold, Qiang Wen, Ross L. Levine, Terra L. Lasho, Zan Huang, Sandeep Gurbuxani, Benjamin Goldenson, Ayalew Tefferi, Animesh Pardanani, Christy Finke, John D. Crispino, Rachael Schultz, Irum Khan, Jessica K. Altman, Laure Gilles
Publikováno v:
Leukemia
The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate i
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19)
Although standard therapy for AML has been relatively constant over the past 2 decades, this may be changing with enhanced technologies allowing for the classification of acute myeloid leukemia (AML) into molecularly distinct subsets. Some specific s